Other Publications Referenced in Amarin’s Investor Communications

Wang X, Verma S, Mason RP, Bhatt DL. The road to approval: a perspective on the role of icosapent ethyl in cardiovascular risk reduction. Curr Diabetes Rep. 2020;20:65. https://link.springer.com/content/pdf/10.1007/s11892-020-01343-7.pdf

Radenkovic D, Olshansky B, Bhatt D. New insights into icosapent ethyl for patients with residual cardiovascular risk. EMJ Cardiol. 2020;8:34-40. https://www.emjreviews.com/cardiology/symposium/new-insights-into-icosapent-ethyl-for-patients-with-residual-cardiovascular-risk/

Bhatt DL. Mechanisms of action, efficacy, and safety of icosapent ethyl: from bench to bedside. Eur Heart J. 2020;22(Supplement J):J1-J2. https://doi.org/10.1093/eurheartj/suaa114

O’Connell TD, Mason RP, Budoff MJ, Navar AM, Shearer GC. Mechanistic insights into cardiovascular protection for omega-3 fatty acids and their bioactive lipid metabolites. Eur Heart J. 2020;22(Supplement J):J3-J20. https://doi.org/10.1093/eurheartj/suaa115

Parhofer KG, Chapman MJ, Nordestgaard BG. Efficacy and safety of icosapent ethyl in hypertriglyceridaemia: a recap. Eur Heart J. 2020;22(Supplement J):J21-J33. https://doi.org/10.1093/eurheartj/suaa116

Olshansky B, Chung MK, Budoff MJ, et al. Mineral oil: safety and use as placebo in REDUCE-IT and other clinical studies. Eur Heart J. 2020;22(Supplement J):J34-J48. https://doi.org/10.1093/eurheartj/suaa117

Ferrari R, Censi S, Cimaglia P. The journey of omega-3 fatty acids in cardiovascular medicine. Eur Heart J. 2020;22(Supplement J):J49-J53. https://doi.org/10.1093/eurheartj/suaa118

Bhatt DL, Hull MA, Song M, Van Hulle C, Carlsson C, Chapman MJ, Toth PP. Beyond cardiovascular medicine: potential future uses of icosapent ethyl. Eur Heart J. 2020;22(Supplement J):J54-J64. https://doi.org/10.1093/eurheartj/suaa119

Boden WE, Baum S, Toth PP, et al. Impact of expanded FDA indication for icosapent ethyl on enhanced cardiovascular residual risk reduction. Future Cardiol. 2020; epub ahead of print. https://www.futuremedicine.com/doi/pdf/10.2217/fca-2020-0106

Toth PP, Shah PK, Lepor NE. Targeting hypertriglyceridemia to mitigate cardiovascular risk: a review. Am J Prevent Cardiol. 2020; epub ahead of print. https://www.sciencedirect.com/science/article/pii/S2666667720300866

Preston Mason, R. New Insights into Mechanisms of Action for Omega-3 Fatty Acids in Atherothrombotic Cardiovascular Disease. Curr Atheroscler Rep. 2019;21:2.

https://doi.org/10.1007/s11883-019-0762-1

Ganda OP, Bhatt DL, Mason RP, Miller M, Boden WE. Unmet Need for Adjunctive Dyslipidemia Therapy in Hypertriglyceridemia Management. J Am Coll Cardiol. 2018;72:330-343.

https://www.sciencedirect.com/science/article/pii/S0735109718348174?via%3Dihub=

Budoff M, Brent Muhlestein J, Le VT, May HT, Roy S, Nelson JR. Effect of Vascepa (icosapent ethyl) on progression of coronary atherosclerosis in patients with elevated triglycerides (200–499 mg/dL) on statin therapy: Rationale and design of the EVAPORATE study. Clin Cardiol. 2018;1–7.
Free:

https://doi.org/10.1002/clc.22856

Watanabe, K. Ando, H. Daidoji, et al., CHERRY study investigators. A randomized controlled trial of eicosapentaenoic acid in patients with coronary heart disease on statins. Journal of Cardiology.2017;70:537-544.

http://www.journal-of-cardiology.com/article/S0914-5087(17)30200-9/fulltext

J.R. Nelson, O. Wani, H.T. May, M. Budoff. Potential benefits of eicosapentaenoic acid on atherosclerotic plaques. Vascular Pharmacology. 2017; 91:1-9.
Free:

http://www.sciencedirect.com/science/article/pii/S1537189116303147?via%3Dihub=

Nordestgaard. Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease: New Insights From Epidemiology, Genetics, and Biology. Circulation.2016;118:547-563.

http://circres.ahajournals.org/content/118/4/547.long